Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Avicanna Inc. (AVCN.TO)
Toronto, ON, CA
Avicanna Inc., a biopharmaceutical firm headquartered in Toronto, Canada, and founded in 2016, is actively engaged in the research, development, and commercialization of scientifically validated products for both global medical and consumer health markets. The company's comprehensive scientific framework encompasses R&D and clinical trials, often undertaken in collaboration with Canadian academic and medical institutions. This effort has yielded around twenty commercialized products spanning four primary market categories. These offerings include medical and wellness items under the RHO Phyto brand, featuring cannabinoids such as CBD, CBG, and THC; CBD-infused topical and derma-cosmetic products marketed under the Pura H&W and Pura Earth labels; and bulk cannabis and hemp-derived raw materials like dried flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, and isolates, provided through the Aureus brand. Additionally, Avicanna is advancing a pharmaceutical pipeline focused on treatments for conditions including epidermolysis bullosa, dermatological ailments, chronic pain, and various neurological disorders. A notable research partnership with Dr. Christine Allen's Research Group is dedicated to developing a cannabinoid-based therapy for lung inflammation linked to COVID-19.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.85% | -7.41% | -13.79% | -26.47% | -53.70% | -44.44% | -50.00% | -71.59% | -87.50% | -97.99% | -97.99% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+0.1% Q1'26: +5.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+31.5% ★ Q1'26: -800.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-9.2% Q1'26: -14.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-10.7% Q1'26: -7.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-24.5% Q1'26: -15.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+14.7% Q1'26: +7.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× Q1'26: 0.00× (vs Q1'25)
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|
| Revenue |
1.57M
est: 3.00M (-47.7%)
|
3.27M
est: 3.10M (+5.5%)
|
4.05M
est: 9.10M (-55.5%)
|
16.79M
est: 15.00M (+11.9%)
|
25.46M
est: 21.00M (+21.2%)
|
25.48M
est: 25.20M (+1.1%)
|
| EBITDA |
-33.70M
est: -2.12M (-1,489.5%)
|
-15.13M
est: -2.19M (-590.6%)
|
-12.18M
est: -6.43M (-89.3%)
|
-7.36M
est: -10.60M (+30.6%)
|
-2.43M
est: -10.97M (+77.8%)
|
-1.97M
est: -13.16M (+85.0%)
|
| EBIT |
-34.79M
est: -2.17M (-1,504.5%)
|
-16.02M
est: -2.24M (-615.2%)
|
-13.06M
est: -6.58M (-98.6%)
|
-8.13M
est: -10.84M (+25.0%)
|
-3.28M
est: -11.42M (+71.3%)
|
-2.72M
est: -13.71M (+80.2%)
|
| Net Income |
-32.86M
est: -69.02M (+52.4%)
|
-16.78M
est: -26.01M (+35.5%)
|
-14.74M
est: -15.00M (+1.8%)
|
-8.74M
est: -6.00M (-45.7%)
|
-3.62M
est: 2.29M (-257.7%)
|
-2.84M
est: 8.03M (-135.4%)
|
| SGA |
16.24M
est: 10.93M (+48.6%)
|
12.88M
est: 11.29M (+14.1%)
|
9.99M
est: 33.14M (-69.9%)
|
13.93M
est: 54.63M (-74.5%)
|
16.06M
est: 35.53M (-54.8%)
|
15.12M
est: 42.64M (-64.5%)
|
| EPS |
-1.12
est: -0.69 (-62.3%)
|
-0.41
est: -0.26 (-57.7%)
|
-0.25
est: -0.15 (-66.7%)
|
-0.10
est: -0.06 (-66.7%)
|
-0.04
est: 0.02 (-281.0%)
|
-0.02
est: 0.07 (-135.4%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aras Azadian Mba | Co-Founder, Chief Executive Officer & Director | 250.0K | male |
| Stephen Kim | Chief Legal Officer, General Counsel & Corporate Secretary | 241.2K | male |
| Karolina Urban | Executive Vice President of Scientific & Medical Affairs | 173.7K | — |
| Ivana Maric | Executive Vice President of Marketing | 165.0K | female |
| Nick Hilborn | Interim Chief Financial Officer | 159.0K | male |
| Ingrid Diaz | Vice President, Assistant General Counsel & Corporate Compliance Officer | — | female |
| Carlos Enrique Maldonado Muete | SVP of Clinical Development | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AVCN.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
